The presence of these clinical–pathological variables allows a more complete and accurate association between the expression of specific biomarkers (ER, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2-HER2-, molecular subtypes) and ILs with breast cancer bone metastasis incidence. This evidence concerns the gene ERBB2 and breast cancer.